Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Advanced glycation end-products (AGES): A novel therapeutic target for osteoporosis in patients with rheumatoid arthritis
- Issue Date
- Aug-2009
- Publisher
- CHURCHILL LIVINGSTONE
- Keywords
- SYNOVIAL-FLUID; BONE LOSS; PENTOSIDINE; COLLAGEN; INFLAMMATION; MECHANISMS; DISEASE
- Citation
- MEDICAL HYPOTHESES, v.73, no.2, pp.201 - 202
- Indexed
- SCIE
SCOPUS
- Journal Title
- MEDICAL HYPOTHESES
- Volume
- 73
- Number
- 2
- Start Page
- 201
- End Page
- 202
- ISSN
- 0306-9877
- Abstract
- Bone losses in patients with rheumatoid arthritis (RA) include focal marginal joint erosion, juxtaarticular osteopenia, and systemic osteoporosis. Systemic osteoporosis prevalent in RA is associated with increased fracture rates and is a cause of very high morbidity and mortality. A couple of reports showed that advanced glycation end-products (AGEs) influence osteoclasts (bone resorption) and osteoblasts (bone formation), so AGEs may be have an important role in the pathogenesis of osteoporotic bone diseases. Recently, it was demonstrated that AGEs is increased in patients with RA and the concentration of AGEs correlates with the disease activity of RA. We present a hypothesis that AGEs may be involved in the pathogenesis of osteoporosis in patients with RA and the AGE crosslink breaker alagebrium will be a powerful therapeutic agent for osteoporosis in patients with RA. (C) 2009 Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Related Researcher
- Ji, Jong Dae
- College of Medicine (Department of Medical Science)